大葉大學圖書館 |

Cancer biomarkers[electronic resource] :minimal and noninvasive early diagnosis and prognosis /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
杜威分類號:	616.99/4
書名/作者:	Cancer biomarkers : minimal and noninvasive early diagnosis and prognosis // edited by Debmalya Barh ... [et al.].
其他作者:	Barh, Debmalya.
出版者:	Boca Raton : : CRC Press/Taylor & Francis Group,, 2014
面頁冊數:	1 online resource (954 p.) : : ill.
標題:	Tumor markers.
標題:	Cancer - Diagnosis.
標題:	Cancer - Treatment.
標題:	Tumor Markers, Biological.
標題:	Early Detection of Cancer.
標題:	Neoplasms - diagnosis.
標題:	Neoplasms - therapy.
ISBN:	9781466584297
ISBN:	1466584297
ISBN:	1306415667
ISBN:	9781306415668
書目註:	Includes bibliographical references.
摘要、提要註:	"According to the American Cancer Society report, "by 2030, the global cancer burden is expected to nearly double, growing to 21.4 million cases and 13.2 million deaths." Early diagnosis improves treatment efficacy and quality of life as well as reduces the cost for disease management. However, the development of molecular markers for early cancer diagnosis is always a challenge. Some fundamental principles in medical practice are (a) primum non nocere, a Latin phrase that means "first, do no harm," and (b) even when a patient's prognosis is poor, the physician must do his or her best for improving quality of the patient's life. Therefore, noninvasive or minimally invasive cancer diagnostic methods are of choice that can avoid complications of biopsy and other unfavorable impacts on patient's health. In this context, patients' easily collectable biospecimens such as blood, serum, plasma, urine, stool, sputum, saliva, etc.-based molecular markers having high specificity and sensitivity in early diagnosis are emerging rapidly and in many instances such markers are also emerging as next-generation prognostic indicators and personalized therapeutics and precision medicine. Several patents have been filed and/or granted on such markers, and a number of health-care companies and authorities currently use or focus on the development of such markers. The significance of clinical validation approaches of several markers has been discussed in different chapters. This book, Cancer Biomarkers: Noninvasive Early Diagnosis and Prognosis, reflects the rapid expansion of important scientific, technological, clinical, and translational aspects of noninvasive or minimally invasive molecular cancer biomarkers and their applications along with other conventional markers"--Provided by publisher.
電子資源:	http://www.crcnetbase.com/isbn/9781466584297

Cancer biomarkers[electronic resource] :minimal and noninvasive early diagnosis and prognosis /
Cancer biomarkers (Barh)

Cancer biomarkersminimal and noninvasive early diagnosis and prognosis /[electronic resource] :edited by Debmalya Barh ... [et al.]. - Boca Raton :CRC Press/Taylor & Francis Group,2014 - 1 online resource (954 p.) :ill.

Includes bibliographical references.

"According to the American Cancer Society report, "by 2030, the global cancer burden is expected to nearly double, growing to 21.4 million cases and 13.2 million deaths." Early diagnosis improves treatment efficacy and quality of life as well as reduces the cost for disease management. However, the development of molecular markers for early cancer diagnosis is always a challenge. Some fundamental principles in medical practice are (a) primum non nocere, a Latin phrase that means "first, do no harm," and (b) even when a patient's prognosis is poor, the physician must do his or her best for improving quality of the patient's life. Therefore, noninvasive or minimally invasive cancer diagnostic methods are of choice that can avoid complications of biopsy and other unfavorable impacts on patient's health. In this context, patients' easily collectable biospecimens such as blood, serum, plasma, urine, stool, sputum, saliva, etc.-based molecular markers having high specificity and sensitivity in early diagnosis are emerging rapidly and in many instances such markers are also emerging as next-generation prognostic indicators and personalized therapeutics and precision medicine. Several patents have been filed and/or granted on such markers, and a number of health-care companies and authorities currently use or focus on the development of such markers. The significance of clinical validation approaches of several markers has been discussed in different chapters. This book, Cancer Biomarkers: Noninvasive Early Diagnosis and Prognosis, reflects the rapid expansion of important scientific, technological, clinical, and translational aspects of noninvasive or minimally invasive molecular cancer biomarkers and their applications along with other conventional markers"--Provided by publisher.

ISBN: 9781466584297Subjects--Topical Terms:

470235
Tumor markers.

LC Class. No.: RC270.3.T84 / C36 2014eb

Dewey Class. No.: 616.99/4

National Library of Medicine Call No.: QZ 241

Cancer biomarkers[electronic resource] :minimal and noninvasive early diagnosis and prognosis /
LDR:03011cam a2200301Ii 4500 001 427806
003 OCoLC
005 20151105015143.0
006 m o d
007 cr |||||||||||
008 151130s2014 flua ob 000 0 eng d
020 $a 9781466584297 $q (electronic bk.)
020 $a 1466584297 $q (electronic bk.)
020 $a 1306415667 $q (ebk)
020 $a 9781306415668 $q (ebk)
020 $z 9781466584280 $q (hardback : $q alk. paper)
035 $a (OCoLC)868928126 $z (OCoLC)866439676 $z (OCoLC)870088303
035 $a ocn868928126
040 $a E7B $b eng $c E7B $d OCLCQ $d OCLCO $d N $d OHS $d EBLCP $d SFB $d UIU $d YDXCP $d TPH $d OCLCF $d CRCPR $d OCLCQ $d OCLCO $d MMU $d IDEBK $d CDX $d OCLCQ $d VLB
050 4 $a RC270.3.T84 $b C36 2014eb
060 4 $a QZ 241
082 0 4 $a 616.99/4 $2 23
130 0 $a Cancer biomarkers (Barh) $3 608923
245 1 0 $a Cancer biomarkers $h [electronic resource] : $b minimal and noninvasive early diagnosis and prognosis / $c edited by Debmalya Barh ... [et al.].
260 $a Boca Raton : $b CRC Press/Taylor & Francis Group, $c 2014
300 $a 1 online resource (954 p.) : $b ill.
504 $a Includes bibliographical references.
520 $a "According to the American Cancer Society report, "by 2030, the global cancer burden is expected to nearly double, growing to 21.4 million cases and 13.2 million deaths." Early diagnosis improves treatment efficacy and quality of life as well as reduces the cost for disease management. However, the development of molecular markers for early cancer diagnosis is always a challenge. Some fundamental principles in medical practice are (a) primum non nocere, a Latin phrase that means "first, do no harm," and (b) even when a patient's prognosis is poor, the physician must do his or her best for improving quality of the patient's life. Therefore, noninvasive or minimally invasive cancer diagnostic methods are of choice that can avoid complications of biopsy and other unfavorable impacts on patient's health. In this context, patients' easily collectable biospecimens such as blood, serum, plasma, urine, stool, sputum, saliva, etc.-based molecular markers having high specificity and sensitivity in early diagnosis are emerging rapidly and in many instances such markers are also emerging as next-generation prognostic indicators and personalized therapeutics and precision medicine. Several patents have been filed and/or granted on such markers, and a number of health-care companies and authorities currently use or focus on the development of such markers. The significance of clinical validation approaches of several markers has been discussed in different chapters. This book, Cancer Biomarkers: Noninvasive Early Diagnosis and Prognosis, reflects the rapid expansion of important scientific, technological, clinical, and translational aspects of noninvasive or minimally invasive molecular cancer biomarkers and their applications along with other conventional markers"--Provided by publisher.
588 0 $a Online resource; title from digital title page (ebrary, viewed on December 23, 2014).
650 0 $a Tumor markers. $3 470235
650 0 $a Cancer $x Diagnosis. $3 338598
650 0 $a Cancer $x Treatment. $3 338599
650 1 2 $a Tumor Markers, Biological. $3 448207
650 1 2 $a Early Detection of Cancer. $3 489044
650 2 2 $a Neoplasms $x diagnosis. $3 403968
650 2 2 $a Neoplasms $x therapy. $3 336986
700 1 $a Barh, Debmalya. $3 608924
856 4 0 $u http://www.crcnetbase.com/isbn/9781466584297